Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Last updated: October 8, 2024
Sponsor: Hannover Medical School
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

blood samples

Clinical Study ID

NCT03798860
DSA-2018
  • All Genders

Study Summary

Single-arm, prospective observational study

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • all patients after lung transplantation with detection of donor-specific antibodies

Exclusion

Exclusion Criteria:

  • none

Study Design

Total Participants: 75
Treatment Group(s): 1
Primary Treatment: blood samples
Phase:
Study Start date:
October 01, 2018
Estimated Completion Date:
December 31, 2026

Study Description

This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.

Connect with a study center

  • Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery

    Hannover,
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.